期刊文献+

LCZ696中间体的合成 被引量:1

Synthesis of an Intermediate for LCZ696
下载PDF
导出
摘要 对LCZ696的关键中间体(R)-叔丁基(1-([1,1′-联苯]-4-基)-3-羟基丙烷-2-基)氨基甲酸酯进行了工艺改进研究,即以价廉易得的甘氨酸甲酯盐酸盐为起始物料,经缩合、N-烷基化、水解、生物酶拆分、Boc酸酐保护、还原获得目标产物,反应总收率37.0%。 The method for the preparation of (R)-tert-butyl (1-([1,1'-biphenyl]-4-yl)-3-hydroxypropan-2-yl) carbamate, a key intermediate for LCZ696, was improved. The target product was synthesized from glycinemethylester hydrochloride via condensation, N-alkylation, hydrolysis, enzymatic resolution, Boc protection and reduction, and an overall yield of 37.0% was obtained.
作者 丛日刚 沈文丽 刘庆春 CONG Ri-gang SHEN Wen-li LIU Qing-chun(Disha Pharmaceutical Group Co., Ltd., Weihai 264205, Chin)
出处 《精细化工中间体》 CAS 2016年第5期22-24,共3页 Fine Chemical Intermediates
关键词 (R)-叔丁基(1-([1 1′-联苯]-4-基)-3-羟基丙烷-2-基)氨基甲酸酯 LCZ696 酶拆分 (R)-tert-butyl(1-([1,1 '-biphenyl]-d-yl)-3-hydroxypropan-2-yl)carbamate LCZ696 enzymatic resolution
  • 相关文献

参考文献2

二级参考文献17

  • 1GASIOROWSKI A, DUTKIEWICZ J. Comprehen- sive rehabilitation in chronic heart failure [J]. Ann Agric Environ Med, 2013, 20: 606--612.
  • 2ZUCKER I H, XIAO L, HAACK K K V, et al. The central RAS and sympathetic nerve activity in chronic heart failure [J]. Clin Sci (Lond), 2014, 126:695-- 706.
  • 3MCMURRAY J J V. CONSENSUS to EMPHASIS; the overwhelming evidence which makes blockade of the renin-angiotensin-aldosterone system the corner- stone of therapy for systolic heart failure [J]. Eur J Heart Fail, 2011,13: 929--936.
  • 4VARDENY O, TACHENY T, SOLOMON S D. First-in-class angiotensin receptor neprilysin inhibitor in heart failure [J]. Clin Pharmacol Ther, 2013, 94: 445--448.
  • 5ORLY VARDENY P, MILLER R, SOLOMON S D. Combined Neprilysin and Renin-Angiotensin System Inhibition for the Treatment of Heart Failure [J]. JACC Heart Fail, 2014, 6: 663--670.
  • 6KOMUKAI K, YAGI H, OGAWA T, et al. Inhibi- tion of the renin-angiotensin system prevents re-hos- pitalization of heart failure patients with preserved e- jection fraction[J]. CircJ, 2008, 72: 2004-2008.
  • 7FERRAR10 C. Effect of angiotensin receptor block- ade on endothelial function: focus on olmesartan med- oxomil[J]. Vasc Health Risk Manag, 2009,5 : 301--314.
  • 8LI C, BOOZE R M, HERSH L B. Tissue-specific ex- pression of rat neutral endopeptidase (neprilysin) mRNAs [J]. J Biolog Chem, 1995, 270: 5723-- 5728.
  • 9STANDEVEN K F, HESS K, CARTER A M, et al. Neprilysin, obesity and the metabolic syndrome [J]. Intern J Obes, 2010, 35: 1031--1040.
  • 10NISHIKIMI T, KUWAHARA K, NAKAO K. Cur- rent biochemistry, molecular biology, and clinical rel- evance of natriuretic peptides [J]. J Cardiol, 2011, 57: 131--140.

共引文献3

同被引文献2

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部